GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » Shares Outstanding (EOP)

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Shares Outstanding (EOP) : 239.11 Mil (As of Jun. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cryofocus Medtech (Shanghai) Co's shares outstanding for the quarter that ended in Jun. 2023 was 239.11 Mil.

Cryofocus Medtech (Shanghai) Co's quarterly shares outstanding stayed the same from Dec. 2022 (239.11 Mil) to Jun. 2023 (239.11 Mil).

Cryofocus Medtech (Shanghai) Co's annual shares outstanding stayed the same from Dec. 2021 (239.11 Mil) to Dec. 2022 (239.11 Mil).


Cryofocus Medtech (Shanghai) Co Shares Outstanding (EOP) Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co Shares Outstanding (EOP) Chart

Cryofocus Medtech (Shanghai) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
239.11 239.11 239.11 239.11

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Shares Outstanding (EOP) Get a 7-Day Free Trial 239.11 239.11 239.11 239.11 239.11

Competitive Comparison of Cryofocus Medtech (Shanghai) Co's Shares Outstanding (EOP)

For the Medical Devices subindustry, Cryofocus Medtech (Shanghai) Co's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryofocus Medtech (Shanghai) Co's Shares Outstanding (EOP) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cryofocus Medtech (Shanghai) Co's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Cryofocus Medtech (Shanghai) Co's Shares Outstanding (EOP) falls into.



Cryofocus Medtech (Shanghai) Co Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Cryofocus Medtech (Shanghai) Co  (HKSE:06922) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Cryofocus Medtech (Shanghai) Co Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Cryofocus Medtech (Shanghai) Co's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Traded in Other Exchanges
N/A
Address
Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120
Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines